Claude Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Claude Martin has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Djillali Annane
Service de Réanimation, Comprehensive Sepsis Centre PROMETHEUS, Hôpital Raymond Poincaré, Assistance Publique-Hôpitaux de Paris, Université Versailles Saint-Quentin, Garches, Versailles, France
3 shared publications - Alain Cariou
Cochin University Hospital (AP-HP) and University Paris Cité (Medical School), Paris, France
2 shared publications - Alain Renault
Service de Pharmacologie, Centre d’Investigation Clinique INSERM 1414, CHU de Rennes, Université de Rennes 1, Rennes, France
2 shared publications - Armand R. J. Girbes
Department of Intensive Care Medicine, Amsterdam Cardiovascular Science (ACS), Amsterdam Medical Data Science (AMDS), Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands
2 shared publications - Benoit Misset
Intensive Care Department and Burn Centre, University Hospital of Liège, University of Liège, 4000 Liège, Belgium
2 shared publications - Bertrand Guidet
Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Equipe PEPITES, AP-HP, Hôpital Saint Antoine, Paris, France
2 shared publications
Latest Publications
- Open Access
- 1 January 2019
- Published by Elsevier in Annals of Intensive Care
- Vol. 9 (1) , 20-12
Current use of vasopressors in septic shock
- 1 January 2019
- Published by Elsevier in Annals of Intensive Care
- Vol. 9 (1) , 20-12
Open AccessCurrent use of vasopressors in septic shock
- Open Access
- 22 December 2018
- Published by Springer Nature in BMC Anesthesiology
- Vol. 18 (1) , 1-14
Choice of fluids in critically ill patients
Fluids are by far the most commonly administered intravenous treatment in patient care. During critical illness, fluids are widely administered to maintain or increase cardiac output, thereby relieving overt tissue hypoperfusion and hypoxia. Until recently, because of their excellent safety profile, fluids were not considered “medications”. However, it is now understood that intravenous fluid should be viewed as drugs. They affect the cardiovascular, renal, gastrointestinal and immune systems. Fluid administration should therefore always be accompanied by careful consideration of the risk/benefit ratio, not only of the additional volume being administered but also of the effect of its composition on the physiology of the patient. Apart from the need to constantly assess fluid responsiveness, it is also important to periodically reconsider the type of fluid being administered and the evidence regarding the relationship between specific disease states and different fluid solutions. The current review presents the state of the art regarding fluid solutions and presents the existing evidence on routine fluid management of critically ill patients in specific clinical settings (sepsis, Adult Respiratory Distress Syndrome, major abdominal surgery, acute kidney injury and trauma).
- 22 December 2018
- Published by Springer Nature in BMC Anesthesiology
- Vol. 18 (1) , 1-14
Open AccessChoice of fluids in critically ill patients
Fluids are by far the most commonly administered intravenous treatment in patient care. During critical illness, fluids are widely administered to maintain or increase cardiac output, thereby relieving overt tissue hypoperfusion and hypoxia. Until recently, because of their excellent safety profile, fluids were not considered “medications”. However, it is now understood that intravenous fluid should be viewed as drugs. They affect the cardiovascular, renal, gastrointestinal and immune systems. Fluid administration should therefore always be accompanied by careful consideration of the risk/benefit ratio, not only of the additional volume being administered but also of the effect of its composition on the physiology of the patient. Apart from the need to constantly assess fluid responsiveness, it is also important to periodically reconsider the type of fluid being administered and the evidence regarding the relationship between specific disease states and different fluid solutions. The current review presents the state of the art regarding fluid solutions and presents the existing evidence on routine fluid management of critically ill patients in specific clinical settings (sepsis, Adult Respiratory Distress Syndrome, major abdominal surgery, acute kidney injury and trauma).
- Open Access
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 79-3
Erratum to: Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 79-3
Open AccessErratum to: Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
- Open Access
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 43-13
Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 43-13
Open AccessDesign and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
- Open Access
- 26 July 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (4) , R166
Re-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl starch in critically ill patients - a multidisciplinary statement
Introduction: Hydroxyethyl starch (HES) is a commonly used colloid in critically ill patients. However, its safety has been questioned in recent studies and meta-analyses. Methods: We re-evaluated prospective randomised controlled trials (RCT) from four meta-analyses published in 2013 that compared the effect of HES with crystalloids in critically ill patients, focusing on the adherence to 'presumably correct indication'. Regarding the definition of 'presumably correct indication', studies were checked for the following six criteria (maximum six points): short time interval from shock to randomisation (<6 h), restricted use for initial volume resuscitation, use of any consistent algorithm for haemodynamic stabilisation, reproducible indicators of hypovolaemia, maximum dose of HES, and exclusion of patients with pre-existing renal failure or renal replacement therapy. Results: Duration of fluid administration ranged from 90 min up to a maximum of 90 days. Four studies considered follow-up until 90-day mortality, three studies 28-/30-day mortality, whereas four studies reported only early mortality. Included studies showed a large heterogeneity of the indication score ranging between 1 and 4 points with a median (25%; 75% quartile) of 4 (2; 4). Conclusions: The most important question, whether or not HES may be harmful when it is limited to immediate haemodynamic stabilisation, cannot be answered yet in the absence of any study sufficiently addressing this question. In order to overcome the limitations of most of the previous studies, we now suggest an algorithm emphasising the strict indication of HES. Additionally, we give a list of suggestions that should be adequately considered in any prospective RCT in the field of acute volume resuscitation in critically ill patients.
- 26 July 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (4) , R166
Open AccessRe-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl starch in critically ill patients - a multidisciplinary statement
Introduction: Hydroxyethyl starch (HES) is a commonly used colloid in critically ill patients. However, its safety has been questioned in recent studies and meta-analyses. Methods: We re-evaluated prospective randomised controlled trials (RCT) from four meta-analyses published in 2013 that compared the effect of HES with crystalloids in critically ill patients, focusing on the adherence to 'presumably correct indication'. Regarding the definition of 'presumably correct indication', studies were checked for the following six criteria (maximum six points): short time interval from shock to randomisation (<6 h), restricted use for initial volume resuscitation, use of any consistent algorithm for haemodynamic stabilisation, reproducible indicators of hypovolaemia, maximum dose of HES, and exclusion of patients with pre-existing renal failure or renal replacement therapy. Results: Duration of fluid administration ranged from 90 min up to a maximum of 90 days. Four studies considered follow-up until 90-day mortality, three studies 28-/30-day mortality, whereas four studies reported only early mortality. Included studies showed a large heterogeneity of the indication score ranging between 1 and 4 points with a median (25%; 75% quartile) of 4 (2; 4). Conclusions: The most important question, whether or not HES may be harmful when it is limited to immediate haemodynamic stabilisation, cannot be answered yet in the absence of any study sufficiently addressing this question. In order to overcome the limitations of most of the previous studies, we now suggest an algorithm emphasising the strict indication of HES. Additionally, we give a list of suggestions that should be adequately considered in any prospective RCT in the field of acute volume resuscitation in critically ill patients.
- Open Access
- 25 July 2012
- Published by Springer Nature in Intensive Care Medicine
- Vol. 38 (9) , 1556-1557
Comments on Reinhart et al.: consensus statement of the ESICM task force on colloid volume therapy in critically ill patients
- 25 July 2012
- Published by Springer Nature in Intensive Care Medicine
- Vol. 38 (9) , 1556-1557
Open AccessComments on Reinhart et al.: consensus statement of the ESICM task force on colloid volume therapy in critically ill patients